One is that BP selection is altered in cancerous cells carrying recurrent mutations in SF3B1 that influence tumor progression (Darman et al. 2015; Alsafadi et al. 2016), and the other is that bacteria produce small molecule splicing inhibitors (Spliceostatin-A, Pladienolide-B, etc.)that block loading of the branch point in to SF3B1 (Yokoi et al. 2011; Cretu et al. 2021). This evidence concerns the gene SF3B1 and neoplasm.